Sophorolipid-based microemulsion delivery system: Multifaceted enhancement of physicochemical properties of xanthohumol

Luo, Jingyang; Yang, Bowen; Yang, Xiao‐Jun; Ji, Shengyang; Guo, Zhiqiang; Liu, Yan; Chen, Qi; Zhao, Tian; Wang, Yixuan; Lu, Baiyi

doi:10.1016/j.foodchem.2023.135631

Cited by 13 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Formononetin has been reported to have antibacterial (Marques das Nevesa et al, 2016), antioxidant (Li et al, 2022) and anti‐inflammatory (Danciu et al, 2018). Xanthohumol also has powerful physiological activities, including antimicrobial, antioxidant and anti‐inflammatory (Luo et al, 2023). Besides, the alkaloids and flavonoids of SF can exert anti‐inflammatory activity via promoting autophagy (Hou et al, 2020; Kan et al, 2020; Wang et al, 2019) and increase the expression of c‐type lysozyme in fish (Li et al, 2019; Zhou et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

In vivo antibacterial activity of medicinal plant Sophora flavescens against Streptococcus agalactiae infection

Zhang

Yang²,

et al. 2023

Journal of Fish Diseases

View full text Add to dashboard Cite

Streptococcosis disease caused by Streptococcus agalactiae (Group B Streptococcus, GBS) results in a huge economic loss of tilapia culture. It is urgent to find new antimicrobial agents against streptococcosis. In this study, 20 medicinal plants were evaluated in vitro and in vivo to obtain medicinal plants and potential bioactive compounds against GBS infection. The results showed that the ethanol extracts of 20 medicinal plants had low or no antibacterial properties in vitro, with a minimal inhibitory concentration ≥256 mg/L. Interestingly, in vivo tests showed that 7 medicinal plants could significantly inhibit GBS infection in tilapia, and Sophora flavescens (SF) had the strongest anti‐GBS activity in tilapia, reaching 92.68%. SF could significantly reduce the bacterial loads of GBS in different tissues (liver, spleen and brain) of tilapia after treated with different tested concentrations (12.5, 25.0, 50.0 and 100.0 mg/kg) for 24 h. Moreover, 50 mg/kg SF could significantly improve the survival rate of GBS‐infected tilapia by inhibiting GBS replication. Furthermore, the expression of antioxidant gene cat, immune‐related gene c‐type lysozyme and anti‐inflammatory cytokine il‐10 in liver tissue of GBS‐infected tilapia significantly increased after treated with SF for 24 h. Meanwhile, SF significantly reduced the expression of immune‐related gene myd88 and pro‐inflammatory cytokines il‐8 and il‐1β in liver tissue of GBS‐infected tilapia. The negative and positive models of UPLC‐QE‐MS, respectively, identified 27 and 57 components of SF. The major components of SF extract in the negative model were α, α‐trehalose, DL‐malic acid, D‐ (−)‐fructose and xanthohumol, while in the positive model were oxymatrine, formononetin, (−)‐maackiain and xanthohumol. Interestingly, oxymatrine and xanthohumol could significantly inhibit GBS infection in tilapia. Taken together, these results suggest that SF can inhibit GBS infection in tilapia, and it has potential for the development of anti‐GBS agents.

show abstract

Section: Discussionmentioning

confidence: 99%

In vivo antibacterial activity of medicinal plant Sophora flavescens against Streptococcus agalactiae infection

Zhang

Yang²,

et al. 2023

Journal of Fish Diseases

View full text Add to dashboard Cite

show abstract

“…A microemulsion delivery system based on commercial biosurfactant sophorolipids (SLs) was developed to improve the solubility and stability of Xanthohumol, a compound with numerous physiological activities such as antioxidant, antimicrobial, anticancer, anti-inflammatory, anti-osteoporosis and neuroprotective activities. The SL-based microemulsion system increased the solubility of Xanthohumol by about 4000 times and extended its half-life to over 150 days, making it a potential green solubilization and delivery method for Xanthohumol and other hydrophobic drugs [ 153 ].…”

Section: Utilizing Biosurfactants As Adjuvants In Medicine: Drug Deli...mentioning

confidence: 99%

Harnessing the Potential of Biosurfactants for Biomedical and Pharmaceutical Applications

Ceresa,

Fracchia,

Sansotera

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Biosurfactants (BSs) are microbial compounds that have emerged as potential alternatives to chemical surfactants due to their multifunctional properties, sustainability and biodegradability. Owing to their amphipathic nature and distinctive structural arrangement, biosurfactants exhibit a range of physicochemical properties, including excellent surface activity, efficient critical micelle concentration, humectant properties, foaming and cleaning abilities and the capacity to form microemulsions. Furthermore, numerous biosurfactants display additional biological characteristics, such as antibacterial, antifungal and antiviral effects, and antioxidant, anticancer and immunomodulatory activities. Over the past two decades, numerous studies have explored their potential applications, including pharmaceuticals, cosmetics, antimicrobial and antibiofilm agents, wound healing, anticancer treatments, immune system modulators and drug/gene carriers. These applications are particularly important in addressing challenges such as antimicrobial resistance and biofilm formations in clinical, hygiene and therapeutic settings. They can also serve as coating agents for surfaces, enabling antiadhesive, suppression, or eradication strategies. Not least importantly, biosurfactants have shown compatibility with various drug formulations, including nanoparticles, liposomes, micro- and nanoemulsions and hydrogels, improving drug solubility, stability and bioavailability, and enabling a targeted and controlled drug release. These qualities make biosurfactants promising candidates for the development of next-generation antimicrobial, antibiofilm, anticancer, wound-healing, immunomodulating, drug or gene delivery agents, as well as adjuvants to other antibiotics. Analysing the most recent literature, this review aims to update the present understanding, highlight emerging trends, and identify promising directions and advancements in the utilization of biosurfactants within the pharmaceutical and biomedical fields.

show abstract

“…Xanthohumol (2) is a principal prenylated chalcone isolated from hops with its anti-inflammatory, anti-oxidative, and cancer-preventive properties ( Zhou et al, 2021 ; Neumann et al, 2022 ; Vicente de Andrade Silva et al, 2023 ).2 protect cardiomyocytes against Fe-SP- and RSL3-induced ferroptosis by decreasing the production of lipid peroxidation and ROS, chelating iron, increasing the Nrf2 and GPX4 protein, while decreasing the mRNA levels of Ptgs2 and Acsl4 , and the protein levels of ACSL4 ( Lin et al, 2022 ). The poor solubility and stability severely limit 2 utilization ( Luo et al, 2023 ). Britanin (3) is a potent inducer of Nrf2( Wu et al, 2017 ).…”

Section: Pharmacological Inhibition Of Ferroptosis For Treating Cardi...mentioning

confidence: 99%

Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy

et al. 2023

View full text Add to dashboard Cite

Cardiomyopathies are a clinically heterogeneous group of cardiac diseases characterized by heart muscle damage, resulting in myocardium disorders, diminished cardiac function, heart failure, and even sudden cardiac death. The molecular mechanisms underlying the damage to cardiomyocytes remain unclear. Emerging studies have demonstrated that ferroptosis, an iron-dependent non-apoptotic regulated form of cell death characterized by iron dyshomeostasis and lipid peroxidation, contributes to the development of ischemic cardiomyopathy, diabetic cardiomyopathy, doxorubicin-induced cardiomyopathy, and septic cardiomyopathy. Numerous compounds have exerted potential therapeutic effects on cardiomyopathies by inhibiting ferroptosis. In this review, we summarize the core mechanism by which ferroptosis leads to the development of these cardiomyopathies. We emphasize the emerging types of therapeutic compounds that can inhibit ferroptosis and delineate their beneficial effects in treating cardiomyopathies. This review suggests that inhibiting ferroptosis pharmacologically may be a potential therapeutic strategy for cardiomyopathy treatment.

show abstract

Sophorolipid-based microemulsion delivery system: Multifaceted enhancement of physicochemical properties of xanthohumol

Cited by 13 publications

References 39 publications

In vivo antibacterial activity of medicinal plant Sophora flavescens against Streptococcus agalactiae infection

In vivo antibacterial activity of medicinal plant Sophora flavescens against Streptococcus agalactiae infection

Harnessing the Potential of Biosurfactants for Biomedical and Pharmaceutical Applications

Targeting ferroptosis as a promising therapeutic strategy to treat cardiomyopathy

Contact Info

Product

Resources

About